Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
Pengfei XuJoy C YangBo ChenChristopher NipJonathan E Van DykeXiong ZhangHong-Wu ChenChristopher P EvansWilliam J MurphyChengfei LiuPublished in: Journal for immunotherapy of cancer (2023)
Our study suggests that immunosuppressive signaling can be promoted directly by enzalutamide-resistant prostate cancer cells and may be a potential means by which the efficacy of immune checkpoint inhibitors in enzalutamide-resistant prostate cancer is diminished.